| Original language | English (US) |
|---|---|
| Pages (from-to) | 66-67 |
| Number of pages | 2 |
| Journal | JAMA cardiology |
| Volume | 6 |
| Issue number | 1 |
| DOIs |
|
| State | Published - Jan 2021 |
Funding
Corresponding Author: Elizabeth McNally, MD PhD, Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Cardiology, Simpson Querrey Biomedical Research Center 5-516, 303 E Superior, Chicago, IL 60611 ([email protected]). Published Online: October 14, 2020. doi:10.1001/jamacardio.2020.4884 Conflict of Interest Disclosures: Dr McNally reported receiving grants from the National Institutes of Health, American Heart Association, and Department of Defense during preparation of this editor’s note; personal fees from Invitae Corp, Tenaya Therapeutics, Amgen, Cytokinetics, Avidity, 4D Molecular Therapeutics, Pfizer, AstraZeneca, and Janssen outside the submitted work; and is Founder, Ikaika Therapeutics (unrelated to content).
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine